Xiaoyun Lu studied Medicinal Chemistry at China Pharmaceutical University and received her Ph.D. in 2010. After working for six years in Guangzhou Institutes of Biomedicine and Health (GIBH), she moved to the School of Pharmacy at Jinan University in 2016. Her research interests include the design of new generation of kinase inhibitors to overcome clinical resistance of cancers. She has been involved in the design and development of EGFR, DDRs, FGFR4, and TRKs inhibitors. Among them, two drug-like inhibitors of kinase have been into clinic. She has published about 100 SCI papers and co-invented 40 patents, received the Special Professor of Changjiang Scholars of Ministry of Education (2024), the National Outstanding Youth Fund (2019), China Pharmaceutical Association - Servier Pharmaceutical Chemistry Award (2014) and Chinese Academy of Sciences Lu Jiaxi Young Talent Award (2015). She currently serves as editorial Board Member of Journal of Medicinal Chemistry, Acta Pharmaceutica Sinica B, Chinese Chemical Letters, etc.

• Part I: Kinase as drug target: An overview1. Introduction to Kinases and Their Functions2. Kinase Inhibitors in Diseases Therapy3. Challenges in Kinase Inhibitors DiscoveryPart II: Strategies in Kinase Drug Discovery4. Screening Approaches for Kinases5. Computational Approaches for Kinases6. Covalent Inhibitors of Kinase7. Macrocyclic Inhibitors of Kinase8. Allosteric Inhibitors of Kinase9. Kinase Degraders10. Kinase ActivatorsPart III: Clinical Indications for Kinase Inhibitors11. Kinase Inhibition for Cancer (Contain Immuno-Oncology)12. Kinase Inhibition for Nononcologic Diseases13. Kinase Inhibition for Non-Catalytic Function